• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, September 22, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Investing in longevity biotechnology: VC panel discusses opportunities at Aging Research and Drug Discovery Conference

Bioengineer by Bioengineer
August 30, 2022
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Investor interest in extending human longevity has never been higher. Analysts estimate that the market to help us live longer will be worth over $600 billion by 2025. On Wed., Aug. 31, as part of the 9th Annual Aging Research and Drug Discovery conference at the University of Copenhagen, a panel of top venture capital investors in longevity biotechnology will talk about opportunities in the space and why they are betting on technologies that will let us live longer and better lives.

Investing in Longevity Biotechnology VC Panel

Credit: Insilico Medicine

Investor interest in extending human longevity has never been higher. Analysts estimate that the market to help us live longer will be worth over $600 billion by 2025. On Wed., Aug. 31, as part of the 9th Annual Aging Research and Drug Discovery conference at the University of Copenhagen, a panel of top venture capital investors in longevity biotechnology will talk about opportunities in the space and why they are betting on technologies that will let us live longer and better lives.

The panel will be moderated by Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, a clinical stage biotech company whose end-to-end artificial intelligence target discovery platform, PandaOmics, has uncovered dual-purpose targets for aging and disease.

Panelists include leading venture capitalists in the longevity biotechnology space, including:

Alexandra Bause, PhD, cofounder at Apollo Heath Ventures which develops interventions with the potential to prevent or reverse age-related diseases and extend healthy human lifespan. Dr. Bause leads the venture creation programs that aim at founding new biotech startups targeting the aging process at a molecular level. She is also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical stage biotech companies.

Mehmood Khan, CEO of Hevolution Foundation. Hevolution is a first of its kind non-profit organization that funds research through grants and provides investments in biotech to incentivize healthspan science across disciplines and borders for the benefit of all. Established by a Saudi Royal Decree with its headquarters in Riyadh with additional international hubs to support the expansion and execute the global mission.

James Peyer, CEO and Co-Founder of Cambrian Biopharma, a partner in the pursuit of expanded healthspan. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm.

Anastasia Georgievskaya, CEO at Haut.AI, a skincare SAAS that is harnessing the power of Artificial Intelligence to slow down or even reverse age-associated changes starting from the first frontier – human skin.

Laurence Ion, Dealflow Steward of VitaDAO, the world’s first decentralized collective funding early stage longevity research with a mission “to extend the human lifespan by researching, financing, and commercializing longevity therapeutics in an open and democratic manner.”

Kristen Fortney, PhD, cofounder and CEO of BioAge, a clinical-stage biotech company that is using  artificial intelligence approaches to identify and target the molecular pathways that drive human aging with a mission to develop a broad pipeline of therapies that increase healthspan and lifespan.

Garri Zmudze, founding partner of LongeVC, a venture capital company supporting early-stage biotech and longevity-focused founders.

 

About the Aging Research & Drug Discovery conference

The 9th annual Aging Research and Drug Discovery (ARDD) conference brings together leading academic and industry speakers in aging research with prominent startups, venture capitalists, and editors of industry journals. The event is being held virtually and in person at the University of Copenhagen Aug. 29-Sept. 2.

Details and registration: http://www.agingpharma.org/ 

 



Share12Tweet8Share2ShareShareShare2

Related Posts

inside cover image

One-stop implementation from signal detection to processing

September 22, 2023
Immune Cells

Australian research leads to clinical trial for rare women’s cancers

September 22, 2023

Ochsner offers tuition assistance to aspiring nurses and doctors

September 22, 2023

Peru’s Operation Mercury stopped most illegal gold mining in one biodiversity hotspot in the Amazon. Then the COVID-19 pandemic hit.

September 21, 2023

POPULAR NEWS

  • blank

    Microbe Computers

    58 shares
    Share 23 Tweet 15
  • University of South Florida scientist: Barnacles may help reveal location of lost Malaysia Airlines flight MH370

    46 shares
    Share 18 Tweet 12
  • Lithuanian invention at the forefront of solar technology breakthrough

    41 shares
    Share 16 Tweet 10
  • A pioneering study from Politecnico di Milano sheds light on one of the still poorly understood aspects of cancer

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

One-stop implementation from signal detection to processing

Australian research leads to clinical trial for rare women’s cancers

Ochsner offers tuition assistance to aspiring nurses and doctors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 57 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In